16:34 EDT Bicara Therapeutics (BCAX) files $400M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAX:
- Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
- Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
- Bicara Therapeutics initiated with a Buy at JonesResearch
- Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
- Bicara Therapeutics initiated with an Overweight at Piper Sandler